2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
1214
Neoplasms
1024
Carcinoma, Non-Small-Cell Lung
851
Prostatic Neoplasms
683
Colorectal Neoplasms
608
Lung Neoplasms
575
Neoplasm Metastasis
431
Multiple Myeloma
420
Leukemia, Myeloid, Acute
394
Pancreatic Neoplasms
371
Ovarian Neoplasms
359
Melanoma
317
Carcinoma, Hepatocellular
284
Recurrence
274
Squamous Cell Carcinoma of Head and Neck
272
Brain Neoplasms
264
Glioblastoma
245
Head and Neck Neoplasms
241
Stomach Neoplasms
236
Precursor Cell Lymphoblastic Leukemia-Lymphoma
226
Carcinoma, Renal Cell
225
Lymphoma
221
Triple Negative Breast Neoplasms
216
Endometrial Neoplasms
207
Hematologic Neoplasms
206
Urinary Bladder Neoplasms
195
Lymphoma, Non-Hodgkin
194
Sarcoma
189
Uterine Cervical Neoplasms
187
Glioma
187
Interventions
Letrozole
2
ribociclib
1
palbociclib
1
abemaciclib
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
HR+/HER2- Breast Cancer
×
90 days
×
Clear all
NCT07492641
2026-06-03
KANDELA-302
BeOne Medicines
Phase 3
Recruiting
1,056 enrolled
NCT06998407
2026-05-04
AVZO-023-1001
Avenzo Therapeutics, Inc.
Phase 1/2
Recruiting
380 enrolled